Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865970 | 0.89 | MAOB (0.52) | MAOBPOLBCYP2C19ALDH1A1MEN1 | |
| SCHEMBL9782658 | 0.87 | MAOB (0.52) | MAOBPOLBCYP2C19ALDH1A1MEN1 | |
| SCHEMBL10969822 | 0.87 | MAOB (0.52) | MAOBPOLBCYP2C19ALDH1A1MEN1 | |
| SCHEMBL566539 | 0.87 | MAOB (0.50) | MAOBPOLBCYP2C19ALDH1A1MEN1 | |
| SCHEMBL8235161 | 0.86 | KMT2A (0.53) | MAOBPOLBCYP2C19ALDH1A1MEN1 | |
| SCHEMBL5583436 | 0.86 | ALDH1A1 (0.53) | MAOBPOLBCYP2C19ALDH1A1MEN1 | |
| SCHEMBL1108184 | 0.85 | MAOB (0.61) | MAOBPOLBCYP2C19ALDH1A1MEN1 | |
| SCHEMBL286962 | 0.85 | MAOB (0.56) | MAOBCYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL12869702 | 0.84 | MAOB (0.48) | MAOBPOLBCYP2C19ALDH1A1MEN1 | |
| SCHEMBL8747352 | 0.84 | MAOB (0.59) | MAOBPOLBCYP2C19ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20170348431-A1 | DRUG DELIVERY POLYMERS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-12-07 | — | — | US | disclosed |
| US-9586988-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586988-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160296631-A1 | DRUG DELIVERY POLYMER AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-10-13 | — | — | US | disclosed |
| US-9381253-B2 | Drug delivery polymer and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-8399614-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120315686-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120315686-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-8153758-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090240029-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | AMBRX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20080317670-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | AMBRX, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080317670-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | AMBRX, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080194459-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080187491-A1 | For diagnosis, genetic engineering; post-translation modification | AMBRX, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080118464-A1 | For diagnosis, genetic engineering; post-translation modification | AMBRX, INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | MAOB 4108/4885POLB 4292/4885CYP2C19 2991/4885 |
| US-20170348431-A1 | DRUG DELIVERY POLYMERS AND USES THEREOF | BRAP, PAICS, BRPF1 | MAOB 4004/4885POLB 361/4885CYP2C19 414/4885 |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | CD74, CD63, CD47 | MAOB 4108/4885POLB 4292/4885CYP2C19 2991/4885 |
| US-20080317670-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | PTMS, DNPEP, ANPEP | MAOB 2019/4885POLB 2009/4885CYP2C19 4690/4885 |
| US-20080118464-A1 | For diagnosis, genetic engineering; post-translation modification | PTMS, ANPEP, AADAT | MAOB 1785/4885POLB 1494/4885CYP2C19 4453/4885 |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AR, PSMA1, NR2E3 | MAOB 4827/4885POLB 2943/4885CYP2C19 4670/4885 |
| US-20160296631-A1 | DRUG DELIVERY POLYMER AND USES THEREOF | BRAP, PSAP, BRPF1 | MAOB 4591/4885POLB 760/4885CYP2C19 652/4885 |
| US-20080187491-A1 | For diagnosis, genetic engineering; post-translation modification | PTMS, ANPEP, AADAT | MAOB 1785/4885POLB 1494/4885CYP2C19 4453/4885 |
| US-20080194459-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, ANPEP, PTMS | MAOB 1925/4885POLB 2746/4885CYP2C19 4541/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | MAOB 3965/4885POLB 4609/4885CYP2C19 3192/4885 |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | KLK3, PTMS, DDOST | MAOB 2845/4885POLB 3618/4885CYP2C19 2985/4885 |
| US-20090240029-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | DNPEP, DDC, PTMS | MAOB 2831/4885POLB 1564/4885CYP2C19 4552/4885 |
| US-20120315686-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DNPEP, ANPEP | MAOB 2019/4885POLB 2009/4885CYP2C19 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.